1. Home
  2. GKOS vs ICL Comparison

GKOS vs ICL Comparison

Compare GKOS & ICL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$113.41

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Logo ICL Group Ltd.

ICL

ICL Group Ltd.

HOLD

Current Price

$5.58

Market Cap

7.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
ICL
Founded
1998
1968
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
7.2B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
ICL
Price
$113.41
$5.58
Analyst Decision
Strong Buy
Hold
Analyst Count
14
3
Target Price
$127.71
$6.23
AVG Volume (30 Days)
641.9K
1.1M
Earning Date
02-19-2026
02-25-2026
Dividend Yield
N/A
3.46%
EPS Growth
N/A
N/A
EPS
N/A
0.29
Revenue
$469,820,000.00
$7,053,000,000.00
Revenue This Year
$31.15
$5.82
Revenue Next Year
$24.15
$5.42
P/E Ratio
N/A
$19.48
Revenue Growth
30.38
1.77
52 Week Low
$73.16
$4.85
52 Week High
$163.71
$7.35

Technical Indicators

Market Signals
Indicator
GKOS
ICL
Relative Strength Index (RSI) 58.14 56.39
Support Level $109.07 $5.49
Resistance Level $115.00 $5.84
Average True Range (ATR) 2.76 0.10
MACD -0.95 0.05
Stochastic Oscillator 44.01 70.79

Price Performance

Historical Comparison
GKOS
ICL

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About ICL ICL Group Ltd.

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates maximum revenue from Brazil followed by, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.

Share on Social Networks: